Result for
Tag: immunity
May 27, 2021
Emergence of a New SARS-CoV-2 Variant from GR Clade with a Novel S Glycoprotein Mutation V1230L in West Bengal India
[Pre-print, not peer-reviewed] Genomic surveillance detected a potential new variant emerging in West Bengal, India from an analysis of over 2,000 sequenced samples collected from January to March 2021. The new variant, identified in 70 of 412 sequences submitted from West Bengal, is characterized by 11 mutations including V1230L and P681H, also found in the…
May 26, 2021
Single-Dose SARS-CoV-2 Vaccine in a Prospective Cohort of COVID-19 Patients
[Pre-print, not peer-reviewed] A study comparing antibody responses in 155 previously SARS-CoV-2 infected individuals found a single dose of the Pfizer-BioNTech vaccine provided neutralizing antibody titers exceeding those produced following two vaccine doses in 49 previously uninfected healthcare workers. Additionally, pre-vaccination neutralization titers in persons with previous infection were associated with higher neutralization titers after…
Influence of Past Infection with SARS-CoV-2 on the Response to the BioTech Pfizer BNT162b2 MRNA Vaccine in Health Care Workers Kinetics and Durability of the Humoral Response
[Pre-print, not peer-reviewed] A cohort study of 63 hospital healthcare workers in Spain who received 2 doses of the Pfizer-BioNTech vaccine found that those with a previous SARS-CoV-2 infection developed a 126-fold increase in antibody levels after 1 dose and maintained higher antibody levels than SARS-CoV-2 naïve workers after the 2nd dose. Healthcare workers with…
May 25, 2021
SARS-CoV-2 Infection Induces Long-Lived Bone Marrow Plasma Cells in Humans
Mean anti-SARS-CoV-2 spike IgG antibody titers exhibited a biphasic decay with a rapid decay during the first 4 months followed by a more gradual decline up to 11 months in an analysis of sera from 77 convalescent individuals, most of whom had recovered from mild COVID-19. Analysis of bone marrow aspirates collected at 7-8 months…
May 24, 2021
Single Dose of BNT162b2 MRNA Vaccine against SARS-CoV-2 Induces High Frequency of Neutralising Antibody and Polyfunctional T-Cell Responses in Patients with Myeloproliferative Neoplasms
Among 21 patients with myeloproliferative neoplasms (MPN), conditions in which the body overproduces blood cells, one dose of the Pfizer-BioNTech vaccine resulted in a positive anti-S IgG ELISA among 76% (n = 16) of patients, neutralizing antibodies in 86% (n = 18) of patients, and a memory T cell response in 80% of patients following…
May 21, 2021
Persistence of SARS-CoV-2-Specific IgG in Children 6 Months After Infection, Australia
A longitudinal cohort study of Australian adults (N=32) and children (N=22) with SARS-CoV-2 infection who were asymptomatic or had mild symptoms detected similar levels of specific IgG antibodies 6 months after infection in both children and adults. There was no significant difference in geometric mean antibody concentration from 43 to 195 days after infection, suggesting…
May 20, 2021
Thrombocytopenia Including Immune Thrombocytopenia after Receipt of MRNA COVID-19 Vaccines Reported to the Vaccine Adverse Event Reporting System (VAERS)
An analysis of reported adverse events following vaccination with an mRNA COVID-19 vaccine indicates that the reported number of thrombocytopenia cases does not suggest a safety concern attributable to mRNA COVID-19 vaccines at this time. Fifteen cases of thrombocytopenia were identified among 18,841,309 doses of Pfizer-BioNTech vaccine and 13 cases among 16,260,102 doses of Moderna…
Diverse Functional Autoantibodies in Patients with COVID-19
Elevated levels of autoantibodies (AAbs) targeting extracellular and secreted proteins that modulate immune response were detected in a cohort of COVID-19 patients (n=194) but not in uninfected controls (n=30). In vitro analysis of the plasma concentrations of these targeted proteins indicate altered immunoreceptor signaling and peripheral immune cell composition, suggesting that the AAbs can impair…
May 19, 2021
Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic SARS-CoV-2 Infection
Vaccine efficacy of 7 COVID-19 vaccines correlated well with reported vaccine-elicited neutralization titers (r=0.9), according to an analysis of phase 3 vaccine trial data. Using data from the trials and neutralization data from cohorts of convalescent patients, the authors estimated that levels of vaccine-elicited anti-SARS-CoV-2 neutralizing antibodies required for 50% protection against detectable SARS-CoV-2 infection…
May 18, 2021
Individuals Who Were Mildly Symptomatic Following Infection with SARS-CoV-2 B.1.1.28 Have Neutralizing Antibodies to the P.1 Variant
[Pre-print, not peer-reviewed] 84% of sera from to individuals (n=60) recovered from mild SARS-CoV-2 infection caused by the B.1.1.28 variant (the wild-type strain circulating in Brazil) had neutralizing antibodies against the P.1 variant of concern. Neutralization titers against the wild-type strain were consistently higher compared to the P.1 variant, but the differences were not more…
Previous page Next page